424B4424B4
Jun 10, 2026Final prospectus0001193125-26-265983
All companies
Trade Parabilis Medicines Inc424B4Jun 10, 2026 Parabilis Medicines files for 25M share IPO at $17-$19/sh Cancer biotech Parabilis Medicines sets terms for $450 million IPO Parabilis Medicines files for IPO to fund cancer drug development After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis Medicines Inc
PBLSPublic
PublicUnited States(NASDAQ Global Select)Best valuation $3.27BSince IPO +37.70%1 market
Public listing
Listed· NASDAQ Global Select· Listing market: United StatesListing date
Jun 10, 2026
Final IPO price
$20.00
Shares offered
33,500,000
Offering proceeds
$670M
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NASDAQIPO
PBLSPrice
$27.54
24h
+6.54%
Valuation
$3.27B
24h volume
$22.89M
Type
IPO
Trade Parabilis Medicines IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
Parabilis Medicines Inc IPO public float & lock-up
Public float and locked shares extracted from Parabilis Medicines Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
1.58M
Public float
33.5M
Locked
-31.92M
IPO raise
$670M
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
About Parabilis Medicines Inc
Parabilis Medicines Inc is an operating company with a business profile centered on its products, services, customers, and execution strategy.
What the company does
- Operates with a business profile defined by its products, services, customers, and operating execution.
- Its durable fundamentals depend on demand for its products or services, margin structure, competitive position, management execution, and capital discipline.
- Primary company filings and official materials are the best source for detailed information about revenue drivers, risk factors, and operating strategy.
Business profile
Parabilis Medicines Inc should be evaluated through its durable business model: what it sells, who it serves, how it generates revenue, and how efficiently it can scale.
SEC IPO filings
Final prospectusEDGAR filings resolved from PBLS / CIK 0001657677.
FWPFWP
Jun 10, 2026Free writing prospectus0001193125-26-264521
Jun 9, 2026Effective9999999995-26-001929
Jun 9, 2026Exchange registration0001354457-26-000549
S-1/AS-1/A
Jun 9, 2026Amended0001193125-26-262880
8-A12B8-A12B
Jun 5, 2026Exchange registration0001193125-26-259552
S-1/AS-1/A
Jun 4, 2026Amended0001193125-26-256398
S-1/AS-1/A
May 27, 2026Amended0001193125-26-242067
S-1S-1
May 19, 2026Filed0001193125-26-230994
Apr 2, 2026Confidential draft0001193125-26-140488
Latest Parabilis Medicines Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
Investing.comJun 4, 2026IPO filing
IPO filing/terms coverage for the same company (shares and indicative price range).
Renaissance CapitalJun 3, 2026IPO filing
IPO terms coverage for Parabilis (offering size/positioning).
Investing.comJun 1, 2026IPO filing
Reports Parabilis Medicines filing for an IPO and details about the offering to list on Nasdaq under PBLS.
BioPharma DiveJun 1, 2026IPO context
Strong IPO context on Parabilis and its rationale/pipeline following private funding.
Parabilis Medicines Inc IPO — frequently asked questions
- When did Parabilis Medicines Inc go public?
- Parabilis Medicines Inc completed its IPO on Jun 10, 2026 on NASDAQ Global Select under the ticker PBLS and now trades publicly.
- What was Parabilis Medicines Inc's IPO price?
- Parabilis Medicines Inc priced its IPO at $20.00 per share.
- Can I buy Parabilis Medicines Inc stock?
- Yes — Parabilis Medicines Inc is publicly traded on NASDAQ Global Select as PBLS. You can follow its live price, valuation and post-IPO performance above.
- What is Parabilis Medicines Inc's valuation?
- Parabilis Medicines Inc's most recent valuation tracked here is $3.27B, derived from live market prices.